Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Q-Cells in Amyotrophic Lateral Sclerosis (ALTA-BOLT)
NCT02478450Phase 2Not yet recruiting
- Sponsor
- Q Therapeutics
- Start
- Dec 2026
- Primary completion
- Dec 2028
- Modality
- Patient-derived iPSCs, Allogeneic iPSCs
01
Overview
Phase 2, open-label trial of Q-Cells in amyotrophic lateral sclerosis (ALS) (6 cohorts), sponsored by Q Therapeutics. Primary endpoint: Safety of human glial restricted progenitor cell transplantation (Adverse Events) at 9 months. Planned start Dec 2026; status: not yet recruiting.
02
Drugs
Q-Cells
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on NCT02478450.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02478450.